AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04281810 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electric diaphragm stimulation
Description: The electrodes were placed on the parasternal region beside the xiphoid process; and the sixth and seventh intercostal spaces in line with the mid-axillary line. TEDS was set as biphasic waves, frequency of 30 Hz, pulse width of 400 μs, and rise time of 0.7s.
Study NCT04449900 — intervention group
Intervention type: OTHER
Intervention: This is observational study with the examination of OCTA
Description: This is observational study with the examination of OCTA
Study NCT01751178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Digluconate Mouthwash with Alcohol
Description: 0.2% w/v Chlorhexidine Digluconate, alcohol containing - UK Marketed Mouthwash
Study NCT04007848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be given at the dose of 40 milligrams once a day (21 days/28). Cobimetinib is available as 20 milligrams film-coated tablets
Study NCT04007848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo will be given at the dose of 40 milligrams once a day (21 days/28). Placebo is available as 20 milligrams film-coated tablets
Study NCT01770093 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Study NCT01291511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloperidone
Description: Over-encapsulated iloperidone tablets were administered orally using a bid schedule; the strengths used include 1, 2, 4, 6, 8, 10, and 12 mg.
Study NCT01291511 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules were administered orally using a bid schedule during the double-blind period.
Study NCT03599544 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Robot-Assisted Therapy (RT)
Description: Highly intensive robot-assisted therapy for the paretic arm with the Armeo exoskeleton (1 hour sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo robot (3x week for 3 weeks).
Study NCT03599544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robot + Active Learning Program(RT-ALPS)
Description: Highly intensive robot-assisted therapy for the paretic arm with the Armeo exoskeleton (1 hour sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo robot (3x week for 3 weeks). In addition, participants will receive training in active problem solving, analysis of performance and goal setting focused on home action plan activities to assist with carry-over and generalization to every day activities.
Study NCT04889690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Study NCT04889690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01804660 — intervention group
Intervention type: OTHER
Intervention: No study treatments administered
Study NCT01379560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: unoprostone isopropyl
Description: 1. unoprostone isopropyl (2 drops)~2. placebo (2 drops)
Study NCT01379560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: unoprostone isopropyl
Description: 1. unoprostone isopropyl (3 drops)~2. placebo (3 drops)
Study NCT00723268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: 5MG Prednisolone per day for 3 months
Study NCT00723268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: 0.5 MG Colchicine per day for 3 months
Study NCT01846689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESS (medical food/drug)
Description: Prescription medical food erythropoietin stimulating system
Study NCT05911945 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible Ureterorenoscopy
Description: A guidewire was placed in the ureter in the lithotomy position. Ureterorenoscopy was performed with an 8 Fr ureterorenoscope for active dilatation. An 11 - 13 Fr or 9.5 / 11.5 Fr UAS was attempted to be placed under fluoroscopy by the surgeon of the procedure. In cases where the UAS could not inserted, a 26 cm, 4.8 Fr JJ stent was placed under fluoroscopy and the procedure was terminated. Patients underwent a second f-URS session, 4 - 6 weeks later. After the JJ stent was removed, an 11 - 13 Fr UAS was placed in the ureter. Digital flexible ureterorenoscope was used as the flexible ureteroscope. Stone fragmentation was performed in dusting mode using a Ho:YAG laser with a 272 µ probe. After fragmentation, a 26 cm 4.8 Fr JJ stent was inserted into the ureter. The JJ stent was removed at 4 - 6 weeks postoperatively.
Study NCT05911945 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini Percutaneous Nephrolithotomy
Description: A guidewire was placed in the ureter in the lithotomy position. Ureterorenoscopy was performed with an 8 Fr ureterorenoscope for active dilatation. An 11 - 13 Fr or 9.5 / 11.5 Fr UAS was attempted to be placed under fluoroscopy by the surgeon of the procedure. In cases where the UAS could not inserted, patients were positioned in prone position and access was performed to the appropriate calyx with an 18-gauge percutaneous access needle using the triangulation technique accompanied by fluoroscopy, in the same session. After the guidewire was introduced into the pelvicalyceal system, sequential dilatation was applied with Amplatz dilatators, and a 21 Fr metallic sheath was placed. Stones were fragmented with a yttrium-aluminum-garnet (Ho:YAG) Laser lithotripter. At the end of the procedure, a 14 Fr nephrostomy catheter was placed in according to the residual stone, hemorrhage, and perforation status. In other cases, the procedure was concluded as totally tubeless.
Study NCT00476398 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Capsule endoscopy
Description: Patient will undergo a capsule endoscopy for the evaluation of their chest pain.
Study NCT01929018 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise will target muscle strength and joint mobility impairments and will be delivered over a 12 week period.
Study NCT01929018 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking Program
Description: A walking program will be established with the goal of participants walking at least five days per week. Duration of program is 12 weeks.
Study NCT01929018 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Self-Management Support
Description: Health self-management support will be delivered with weekly meetings between the researcher and participant over a 12-week period.
Study NCT03996889 — intervention group
Intervention type: DEVICE
Intervention: Endovascular treatment of aneurysms of the popliteal artery by GORE VIABAHN® stent in elective surgery
Description: The intervention can be performed under local anesthesia (LA), regional locus (ALR) or general anesthesia (AG) (data collected) by first approach: percutaneous or conventional.~The data collected are:~* Number of GORE VIABAHN® stent used (length and diameter of each)~* Embolization of collaterals and other related actions~* Operative complications~* Intraoperative fibrinolysis~* Collar cover> 2 cm~* Lack of overlap in the overlap zone (nb: between 4 and 8 cm above the joint spacing)~* Arteriography in profile, kink
Study NCT00069017 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-522
Description: MEDI-522 is formulated in a sterile isotonic solution of 10 mM histidine-HCl at pH 6 containing 100 mg of MEDI-522 protein at a concentration of 100 mg/mL.
Study NCT01751178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Digluconate Mouthwash without Alcohol
Description: 0.2% w/v Chlorhexidine Digluconate, without alcohol - UK Marketed Mouthwash
Study NCT03374397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Surgiguard
Description: Hemostasis with Surgiguard during laparoscopic unilateral ovarian cystectomy
Study NCT00069017 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for MEDI-522 contains 10 mM histidine-HCl at pH 6, 0.1% Tween-80, 1.5% Mannitol, 4.3 µg/mL Vitamin B12, and 2 µg/mL D\&C Yellow #10.
Study NCT04762784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab treatment: Tocilizumab infusion 8mg/Kg，Once per month for 3 months.
Study NCT04762784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks to equal to or less than 15mg per day in 3 months.
Study NCT02385500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: For each phase of the study, the participants will receive a total of 84 pills of fesoterodine 4 mg. The study medication will be provided by Pfizer.~For blinded distribution, each bottle of medications will be labeled with a random number for identification. The participant will indicate in a journal the dose taken each day.~The study participants will be monitored every 2 weeks with phone calls to assess tolerance or side-effects to the medication.
Study NCT02385500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fesoterodine
Description: For each phase of the study, the participants will receive a total of 84 pills of fesoterodine 4 mg. The study medication will be provided by Pfizer.~For blinded distribution, each bottle of medications will be labeled with a random number for identification. The participant will indicate in a journal the dose taken each day.~The study participants will be monitored every 2 weeks with phone calls to assess tolerance or side-effects to the medication.
Study NCT02385500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: For each phase of the study, the participants will receive a total of 84 placebo pills. The study medication will be provided by Pfizer.~For blinded distribution, each bottle of medications will be labeled with a random number for identification. The participant will indicate in a journal the dose taken each day.~The study participants will be monitored every 2 weeks with phone calls to assess tolerance or side-effects to the medication.
Study NCT02385500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For each phase of the study, the participants will receive a total of 84 placebo pills. The study medication will be provided by Pfizer.~For blinded distribution, each bottle of medications will be labeled with a random number for identification. The participant will indicate in a journal the dose taken each day.~The study participants will be monitored every 2 weeks with phone calls to assess tolerance or side-effects to the medication.
Study NCT02587260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
Study NCT02587260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
Study NCT03193944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-vitin, soft gelatin capsule (vitamin D3,50000 IU)
Description: Intervention group: The respondents in intervention group will receive 50000 vitamin D for 8 weeks. Plus, brochures and pamphlets related to nutrition and health.
Study NCT03193944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vitamin D3
Description: vitamin D as a placebo
Study NCT03348813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV/STI Prevention Intervention
Description: The targeted HIV/STI risk reduction intervention was delivered with groups of up to 8 participants through 8, 45-minute modules equally divided over 2 days (4 modules per session). It was designed to enhance participants' knowledge and ability to reduce their risk of HIV/STIs. Grounded in both social/behavioral and cognitive theories, the intervention includes psychoeducation, and was intended to enhance participants' HIV/STI prevention knowledge, attitudes, beliefs and skills in a manner relevant to Black adolescents.
Study NCT03348813 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Control Intervention
Description: The original Promoting Health among Teens (PHAT) Project was designed to increase knowledge and motivation regarding healthful dietary practices, aerobic exercise, and breast and testicular self-examination, and to discourage cigarette smoking. The 8-hour, 2-session PHAT intervention was shortened to mirror the Project GOLD HIV/STI risk reduction curriculum. This was done to control for the Hawthorne effect and reduce the likelihood that effects of the HIV/STI risk reduction intervention can be attributed to its nonspecific features, including special attention. From an ethical standpoint, adolescents in both conditions received a valuable and engaging health-risk-reduction intervention as opposed to usual care.
Study NCT02418481 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combination
Description: γδ T/DC-CIK cells will be used against breast tumor.
Study NCT01118286 — intervention group
Intervention type: DRUG
Intervention: Nifedipine (Adalat, BAYA1040)
Description: Previously untreated hypertensive adult patients starting with combination therapy containing nifedipine or insufficiently controlled hypertensive patients receiving nifedipine as an add-on to existing non-CCB containing antihypertensive therapy. The decision of including the patient as well as decision on dosage and duration is taken by the investigator.
Study NCT02587260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
Study NCT04785976 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical clipping and endovascular coiling
Description: Surgical clipping: Apply aneurysm clip to clip the ruptured aneurysm. Endovascular coiling：Also called endovascular embolization, to block blood flow into an aneurysm.Preventing blood flow into an aneurysm helps to keep it from rupturing.
Study NCT01084369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: NEBIDO ampoules containing a solution for injection of 1000mg/4ml of testosterone undecanoate. NEBIDO injection 1000mg/4ml will be given at baseline, 6 weeks, 18 weeks, 30 weeks, 42 and 54 weeks. Levitra will be given to those patients with erectile dysfunction for 2 weeks in addition to Nebido.~Concomitant medication deemed necessary by the investigator as part of the routine clinical management will be permissable.
Study NCT00407797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: 150 to 600 mg/day during 21 weeks
Study NCT02505204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: The anesthetic mixture will contain: lidocaine 2% 7 mL, lidocaine 2% 6 mL with epinephrine 5µg.mL-1, bupivacaine 0.5% 5 mL, and clonidine 2 mL.
Study NCT02505204 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the same anesthetic mixture will be administrated however the clonidine will be substituted with 2 mL saline.
Study NCT00919919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: progesterone
Description: Daily use of 100 mg progesterone vaginal tablet, and Estrofem; estradiol 1 mg administrated orally. for 6 month
Study NCT00919919 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: activella
Description: Daily use of 1 mg estradiol and 0.5 mg norethindrone acetate administrated orally
Study NCT01201018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oshadi D, Oshadi R
Description: Oral administration
Study NCT03137290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: The TOF Watch Sx, and Paediatric Bispectral Index (BIS) monitoring were put on patient. Gaseous induction, with oxygen and Sevoflurane was given until BIS was 40-50, then a intravenous line was obtained. 2 mcg/kg of fentanyl was given for analgesia. then,the TOF Watch Sx was calibrated.The patient was paralyzed with 0.6mg/kg of rocuronium, and intubation of the trachea was done once TOF count was less than 1. A maintenance of 0.2 mg/kg of Rocuronium was given boluses every 30 minutes to maintain TOF count between 2-3. At the end of surgery, TOF count was checked to ensure it was between 2-3. Then a reversal dose for TOF count of 2 to 3 was 0.05 mg/kg of Neostigmine with 0.02 mg/kg of Atropine. Therefore the volume would be 0.2 mls per kg is to be administered.
Study NCT03137290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex Sodium
Description: The TOF Watch Sx, and Paediatric Bispectral Index (BIS) monitoring were put on patient. Gaseous induction, with oxygen and Sevoflurane was given until BIS was 40-50, then a intravenous line was obtained. 2 mcg/kg of fentanyl was given for analgesia. then,the TOF was calibrated.The patient was paralyzed with 0.6mg/kg of rocuronium, and intubation of the trachea was done once TOF count was less than 1. A maintenance of 0.2 mg/kg of Rocuronium was given boluses every 30 minutes to maintain TOF count between 2-3. At the end of surgery, TOF count was checked to ensure it between 2-3. Then the dose for reversal of sugammadex with a TOF count of 2 or 3 would be 2 mg/kg. This will also be equivalent to a volume of 0.2 mls per kg and given at the end of surgery.
Study NCT01095783 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: physiotherapeutic intervention
Description: Twenty repetitive exercises (30 seconds per exercise) consisting of: flexion in standing, extension in standing, flexion in lying, and extension in lying position applied three times a week for eight weeks
Study NCT01095783 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: control
Description: The control group receive transcutaneous electrical nerve stimulation (TENS) for 20 min at 50-100 Hz frequencies for the same time frame (Anesth Analg 2004;98:1552-6)
Study NCT02706691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGJ398
Description: Given by mouth (oral)
Study NCT03033394 — intervention group
Intervention type: DRUG
Intervention: Beta-lactam antibiotic
Description: Routine clinical dosing
Study NCT01619423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PledOx (2 µmol/kg)
Description: PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles.
Study NCT01619423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PledOx (5 µmol/kg)
Description: PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles
Study NCT01619423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PledOx (10 µmol/kg)
Description: PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles
Study NCT01619423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0,9% NaCl)
Description: Placebo (0,9% NaCl) is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles.
Study NCT04382339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOF/RBV/PegINFα-2
Description: SOF: block the hepatitis C NS5B protein. RBV: a nucleoside inhibitor PegINFα-2: chemically modified form of the standard interferon that treats hepatitis C
Study NCT03704480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500mg by intravenous (IV) infusion on D1 until progression or unacceptable toxicity or withdrawal of consent
Study NCT03704480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 300mg by IV infusion on D1 at cycle 1 only
Study NCT04343963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyridostigmine Bromide
Description: One 60mg tablet P.O. once per day for 14 days
Study NCT04343963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet P.O. once per day for 14 days
Study NCT03338374 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biventricular pacemaker
Description: All subjects will receive a biventricular pacemaker at implantation. Programming will initially be to dual-chamber, dual-function rate-responsive pacing for 12 weeks; following reassessment, device will be reprogrammed to biventricular pacing for a further 12 weeks. Optional study extension: if incremental benefit is shown for biventricular pacing above dual chamber, the mechanism will be sought using echocardiographic evidence and the devices will be optimised according to this mechanism of action to see whether further benefit can be achieved.
Study NCT03925974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN026 10 mg/kg QW
Description: 10 mg/kg QW as safety run-in dosage
Study NCT03925974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN026 20 mg/kg Q2W
Description: 20 mg/kg Q2W as target dosage
Study NCT03925974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN026 30 mg/kg Q3W
Description: 30 mg/kg Q3W as another target dosage
Study NCT01815593 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation
Description: Enhanced external counterpulsation therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole. The systolic deflation/ Diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner. The patients receive 35-36 hours EECP intervention, 1 -hour session every day over a 7-week period.